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Abstract  
This study investigated the influence of the rate of nicotine metabolism, as indicated by the 
nicotine metabolite ratio (NMR) on tobacco dependence. We stratified 136 smokers based on 
saliva NMR as fast (n=65) and slow (n=71) metabolizers. Two “loading cigarettes” were 
smoked after overnight, and a “reward cigarette” after six hours daytime abstinence. Blood 
nicotine concentrations, expired carbon monoxide, withdrawal/craving and reward 
questionnaires were collected before/after smoking and during daytime abstinence. Compared 
to slow, fast metabolizers had shorter nicotine elimination half-life (p<0.001), lower plasma 
nicotine concentrations (p<0.001) and higher withdrawal/craving scores (p<0.05) for most 
times during daytime abstinence, indicating that fast metabolizers are likely smoking more to 
relieve withdrawal symptoms (negative reinforcement). Reward/satisfaction scores were 
similar in fast and slow metabolizers, suggesting that faster nicotine metabolism assessed by 
NMR is not associated with greater positive reinforcement. CYP2A6 normal (n=82) and 
reduced (n=42) genotype predicted plasma nicotine concentrations but not withdrawal 
symptoms. 
 
Introduction 
Nicotine dependence underlies tobacco dependence and sustains cigarette smoking, which 
remains a major cause of premature death [1]. Nicotine dependence is motivated by seeking 
rewarding effects (e.g. stimulation, pleasure), also termed positive reinforcement, and 
reversing aversive effects of nicotine withdrawal (irritability, anxiety, difficulty 
concentrating, etc), also called negative reinforcement.  
Nicotine is metabolized primarily by the hepatic cytochrome P450 enzyme CYP2A6, with 
approximately 80% of nicotine converted to cotinine (COT), which is further metabolized by 
the same enzyme to 3’-hydroxycotinine (3HC) [1]. There is wide individual variability in the 
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clearance of nicotine, due both to genetic variation and environmental and hormonal factors. 
The ratio of 3HC/COT, also called the nicotine metabolite ratio (NMR), is a phenotypic 
biomarker that can be measured in plasma, urine and saliva and is correlated with the rate of 
nicotine clearance [2]. The NMR accounts for both genetic and non-genetic influences of 
CYP2A6 activity, is reproducible within subjects, and independent of the time since last 
cigarette smoked [3-5].  
The rate of nicotine metabolism is an important determinant of tobacco and nicotine 
dependence. Faster nicotine metabolism is associated with greater dependence/higher tobacco 
consumption and lower rates of quitting without pharmacotherapy and with transdermal 
nicotine patch compared to slower metabolizers [6-11]. One potential mechanism for this 
association is that fast metabolizers experience more severe craving/withdrawal and thus are 
more likely to smoke to relieve such symptoms, i.e. for negative reinforcement [7,12]. This 
hypothesis is supported by findings showing that smokers with higher NMR experience more 
anxiety, insomnia, difficulty concentrating, anger and impatience during abstinence [6,13]. 
Another possible mechanism is that due to the faster elimination of nicotine, tolerance to 
psychoactive effects dissipates more rapidly, and therefore subsequent nicotine exposures 
(i.e. cigarette smoking) are more rewarding, that is, positive reinforcement may be greater 
among faster metabolizers. In support of this idea, brain imaging studies show that fast 
metabolizers exhibit greater reactivity in dopamine-dependent reward circuitry when given 
visual smoking cues than slow metabolizers (defined here as the highest and lowest NMR 
quartile, respectively) [14]. 
Smoking behavior, severity of dependence and the rate of nicotine metabolism vary by race 
[15,16]. On average Blacks metabolize nicotine more slowly, due to higher frequency of 
several slow metabolism variants of CYP2A6 and UGT2B10 genes, the latter of which codes 
the UDP-glucuronosyltransferase (UGT) isoform mainly responsible for nicotine 
glucuronidation [10,17-21] and smoke fewer cigarettes per day (CPD) [22]. Although one 
may expect that their slower nicotine metabolism and reduced CPD may be associated with 
less severe nicotine dependence, Blacks report greater difficulty quitting than Whites [15], 
suggesting higher nicotine dependence. The paradox between slower metabolism and higher 
dependence may be related to greater smoking intensity observed previously in Blacks 
compared to Whites [22], but also other factors unrelated to nicotine metabolism. 
Sex differences also present some paradoxes; women metabolize nicotine faster than men due 
to estrogen-mediated induction of CYP2A6 [23,24] but smoke on average fewer CPD [22], 
while the nicotine intake per cigarette is on average the same in both sexes [25]. Most clinical 
trials studying NMR do not find a sex difference in quit rates, indicating that the nicotine 
metabolism rate predicts cessation success in women as well as in men [7-10].  
Aim of the present study was to investigate the association of NMR with withdrawal/craving 
symptoms after abstinence from smoking and the response to smoking a cigarette as assessed 
by questionnaire scores, nicotine plasma concentration, expired carbon monoxide (CO) and 
heart rate (HR) changes after two different abstinence periods, i.e. overnight and six hours 
during the day. We hypothesized that fast, relative to slow, metabolizers will demonstrate 
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more severe withdrawal symptoms and greater craving to smoke during abstinence and more 
reward after subsequent smoking. Furthermore, we aimed to investigate possible racial 
differences of these mechanistic relationships, and also to compare NMR to CYP2A6 
genotype as a biomarker of withdrawal effects. 
 
Results 
A total of 552 potential participants were scheduled for an in-person screening visit. Among 
them, 275 did not meet eligibility (e.g. COT< 50 ng/mL, vital signs not within normal range) 
and 106 did not meet the study’s NMR cut points. From the remaining 171, 34 
declined/didn’t complete the study. A total of 137 participants completed the study, but one 
participant with nicotine concentrations below limit of quantification (LOQ) and very low 
CO was excluded from analysis as it is assumed that this participant did not inhale smoke 
from the cigarettes during the study. Finally, 136 participants were included in the final 
analysis, 71 slow metabolizers and 65 fast metabolizers by NMR.  
 
Baseline characteristics 
The NMR frequency histogram can be found as supplementary information (Figure S1). 
Table 1 shows the baseline characteristics, as well as comparisons based on NMR, race and 
sex. Significant correlations were found between saliva and plasma NMR (r=0.708, p<0.001), 
saliva NMR and nicotine half-life (r= -0.432, p<0.001), and saliva NMR and saliva COT (r=-
0.349, p<0.001). Comparisons within NMR groups by race and by sex can be found as 
supplementary information (Table S1 and Table S2). Complete CYP2A6 genotyping was 
available for 124 participants (91.2%; not available in 12 cases due to incomplete genotype 
results (n=11) or DNA not available (n=1)). Among them, 82 (66.1%) were normal 
metabolizers (NM) (median NMR 0.47, range 0.08-1.1) and 42 (33.9%) reduced metabolizers 
(RM) (median NMR 0.18, range 0.06-0.72). Thirty-three of 42 RM (78.6%) were NMR slow 
metabolizers, while for 50 of the 82 NM (61%) the NMR was indicative for fast metabolism 
(Fig. 1). Analysis of the baseline characteristics using the genotype (i.e. NM vs RM) showed 
significant higher NMR in the NM group (p<0.001), but no significant differences regarding 
other parameters.  
 
Association of nicotine metabolism as assessed by NMR with withdrawal/craving  
Table 2 shows the association of NMR with withdrawal/craving outcomes after the two 
abstinence periods. In a within-subject comparison, the PANAS (Positive and Negative 
Affect Schedule) negative score was significantly higher after overnight compared to daytime 
abstinence (p<0.001), while the Tiffany Questionnaire on Smoking Urges-Brief (QSU) 
Global Craving Score neared significance (p=0.05). Compared to slow, fast metabolizers did 
not demonstrate more severe craving/withdrawal symptoms after overnight abstinence; 
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however, significantly higher craving and withdrawal and PANAS negative scores nearing 
significance were seen after six hours daytime abstinence. When comparing only Whites 
(n=98), significant differences were seen regarding nicotine concentrations (lower in fast 
compared to slow metabolizers both after overnight and daytime abstinence (p<0.001)), but 
not for HR, CO or craving scores. When analyzing only Blacks (n=38), fast metabolizers had 
significantly lower nicotine concentrations (p=0.008) and expired CO (p=0.022) after 
overnight abstinence compared to slow metabolizers, as well as after daytime abstinence 
(p=0.01 and 0.003, respectively). Using the genotypes, significant differences were seen only 
regarding nicotine concentrations (lower in NM compared to RM both after overnight 
(p=0.011) and after six hours daytime abstinence (p=0.003)). 
 
Association of nicotine metabolism as assessed by NMR with rewarding effects  
Table 3 shows the association of NMR with the response to smoking after abstinence. 
Significant score differences (higher craving and withdrawal, and lower satisfaction in fast 
metabolizers compared to slow metabolizers) were seen after the first cigarette of the day 
(Cig 1) but not after Cig 3.When analyzing only Whites or using the genotypes, no significant 
differences were found. Analysis of Blacks only revealed significantly lower nicotine 
concentrations (p=0.04), expired CO (p=0.003) and higher craving (p=0.019) after Cig 1, as 
well as lower expired CO (p=0.024) after Cig 3 in fast compared to slow metabolizers. 
 
Nicotine concentrations and scores over time 
Figure 2 shows the nicotine plasma concentrations over time, by NMR and genotype. Fast 
metabolizers had significantly lower area under the nicotine concentration-time curve (AUC) 
compared to slow metabolizers by NMR (34.1 (8.4-68.6) vs 48.8 (15.0-125.4), p<0.001) and 
by genotype (37.0 (8.4-79.4) vs 46.2 (18.0-125.4), p=0.001). When analyzing the two races 
separately, these differences remained among Whites by NMR (34.9 (10.9-68.6) vs 49.0 
(15.0-91.2), p<0.001) and by genotype (36.6 (10.9-79.4) vs 45.4 (18.2-91.2), p=0.012), and 
among Blacks by NMR (30.2 (8.4-50.5) vs 46.6 (20.2-125.4), p=0.003) but not by genotype 
(p=0.058). Whites had significant differences (fast lower concentrations compared to slow 
NMR) for every time point except post-Cig 1, post-Cig 2 and post-Cig 3, while Blacks for 
every time point except post-Cig 3.  
Figures 3 and 4 show the Minnesota Nicotine Withdrawal Scale (MNWS) and QSU, 
respectively, over time, by NMR and genotype. Significant differences between fast and slow 
metabolizers were seen for the MNWS and QSU craving scores at various time points using 
the NMR but not with the genotype. Using the area under the effect-time curve (AUEC), fast 
metabolizers had significantly higher MNWS-AUEC (39.3 (10.9-185.3) vs 35.9 (0.32-112.3), 
p=0.02) and QSU-AUEC (20.8 (8.4-42.0) vs 16.6 (6.7-36.5), p=0.005) compared to slow 
metabolizers by NMR, but not by genotype. No significant MNWS differences were seen 
between fast and slow metabolizers when analyzing only Whites or Blacks. Analysis of the 
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QSU craving over time in Whites showed significantly higher scores among fast compared to 
slow metabolizers at 1, 2 and 3 hours, and in Blacks post-Cig 1. In Whites, the QSU-AUEC 
was higher among fast compared to slow metabolizers by NMR (20.8 (8.4-42.0) vs 17.6 (8.4-
36.5), p=0.029) but not by genotype, while no significant differences were found in Blacks. 
Regarding other scores (i.e. PANAS, modified Cigarette Evaluation Scale (mCES)), no 
significant differences were seen by NMR except higher mCES satisfaction in slow compared 
to fast metabolizers post-Cig 1 (Table 3). Analysis of only Blacks or Whites showed no 
significant differences by NMR regarding those scores. Using the genotypes, a significant 
difference was seen for the 4h PANAS negative score (higher among NM compared to RM, 
p=0.036).  
 
Boosts and changes 
Investigation of pre- to post-smoking boosts and changes of nicotine, CO, HR and MNWS, 
QSU craving and PANAS showed no significant differences between NMR groups. Similar 
results were found when analyzing only Whites or Blacks, while analysis based on genotypes 
showed greater CO boost after Cig 3 in RM compared to NM (p=0.009). Cig 3 CO and 
nicotine boosts were significantly higher than Cig 1 (p<0.001), while Cig 3 HR changes were 
significantly lower than Cig 1 (p=0.003). 
 
Explorative general linear model (GLM) analysis 
After individual exploration of age, body mass index (BMI), and urine total nicotine 
equivalents (TNE), age emerged as potentially significant covariate and was included in the 
GLM analysis together with sex and race. NMR emerged as a significant covariate for mCES 
respiratory tract sensations (p=0.047) but not for other responses. Sex emerged as significant 
covariate for MNWS pre-Cig 1 (p=0.022), MNWS and craving during daytime abstinence 
(p=0.011 and p=0.007, respectively, higher scores in females), and PANAS positive post-Cig 
3 (p=0.027, higher scores in males). Age was significant for PANAS negative during daytime 
abstinence (p=0.047, higher scores among older participants), PANAS positive post-Cig 3 
(p=0.026 and p=0.022, respectively), mCES reward (Cig 1 p=0.007, Cig 2 p=0.045, Cig 3 
p=0.045) and respiratory tract sensations (Cig 1 p=0.001, Cig 2 p=0.002, Cig 3 p=0.004) 
(higher scores among younger participants). Race emerged as statistically significant 
covariate for mCES satisfaction (post-Cig1 p=0.017, post-Cig 2 p=0.021) (higher scores in 
Whites).  
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Discussion 
We found that fast metabolizers by the phenotypic biomarker NMR had shorter nicotine 
elimination half-lives, lower plasma nicotine concentrations and greater craving/withdrawal 
(as assessed by significant higher AUEC and withdrawal/craving scores for most times 
during abstinence and PANAS negative scores nearing significance at six hours) compared to 
slow metabolizers over six hours daytime cigarette abstinence. This supports the hypothesis 
that the NMR is associated with physical dependence and the idea that fast metabolizers are 
likely smoking more for negative reinforcement. The differences in withdrawal symptoms 
appear relative quickly after smoking the last cigarette. Many of the effects persisted when 
analyzing Blacks and Whites separately, thus indicating that associations with NMR were not 
due to confounding by race.  
We did not confirm the hypothesis of positive reinforcement, as indicated by the absence of 
significant NMR group differences in satisfaction/reward and PANAS positive questionnaires 
and physiological measurements (e.g. HR changes). Furthermore, despite significant 
differences in nicotine concentration and the longer abstinence duration, withdrawal/craving 
scores were higher but not significantly different in fast compared to slow metabolizers after 
the overnight abstinence, possibly because the latter usually represents a normality in 
smokers’ daily routine, thus triggering less withdrawal/craving effects than during six hours 
daytime abstinence. Based on our study, the non-invasive NMR appears to be a better 
biomarker of withdrawal effects than the CYP2A6 genotype. This is consistent with the idea 
that nicotine metabolism is also mediated by other genes and environmental factors.  
Previous studies have shown an association of fast NMR with lower nicotine levels and 
stronger craving one week into a quit attempt with transdermal nicotine [7] and higher 
withdrawal after 24 hour abstinence in adolescent smokers [6]. Smokers in the top NMR 
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quartile had greater craving compared to those in the lowest quartile following overnight 
abstinence [12], while in a study with community-based samples fast metabolizers 
experienced significantly higher anxiety compared to slow metabolizers with transdermal 
nicotine treatment [13]. Despite differences and limitations of those studies (e.g. small 
sample size in the adolescent study), these findings all support that fast metabolizers 
experience more severe withdrawal/craving during abstinence associated with differences in 
the rate of nicotine metabolism.  
The observation that faster nicotine metabolism is associated with more severe withdrawal 
symptoms has important clinical implications. Withdrawal symptoms can present a major 
obstacle to smoking cessation and increase relapse risk [26,27]. Therefore, specific 
supporting measures (e.g. higher than standard nicotine replacement doses [7], behavioral 
intervention [13], use of varenicline to relieve craving/withdrawal symptoms [11,28]), should 
be considered for smokers with high NMR attempting to quit. However, other studies [8,9] 
failed to find an association between high NMR and craving/withdrawal, possibly due to 
methodological and sample differences (e.g. use of bupropion and not nicotine replacement 
therapy [8]). 
Positive reinforcement is another suggested mechanism for the greater dependence and lower 
quitting rates in fast metabolizers. This is supported by a brain imaging study in which fast 
metabolizers exhibited greater reactivity in dopamine-dependent reward circuitry after visual 
smoking cues [14] and a study with administration of nicotine intravenously following 
overnight abstinence [12]. Possible reasons for the different findings in our study might be 
stronger reward effects after intravenous administration of nicotine compared to smoking, 
and differences between neural responses in functional magnetic resonance imaging (fMRI) 
and subjective feelings of reward. 
Our data are consistent with previous findings that Blacks have on average slower nicotine 
metabolism compared to Whites [10,17-21]. Blacks also smoke fewer CPD [29], which could 
be related to slower metabolism [30], but also more intensive smoking [31] and higher 
nicotine intake per cigarette [22]. Blacks and slow NMR participants had higher COT levels 
despite lower TNE, consistent with other pharmacokinetic observations on effects of reduced 
CYP2A6 activity on COT levels [32,33]. Separate analysis of Blacks showed significant 
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differences in nicotine concentration and expired CO between fast and slow NMR at more 
time points compared to Whites, but less significant differences in craving scores, possibly 
due to the smaller sample size. Our findings further indicate possible higher reward effects in 
Whites, which might be associated with racial or NMR differences. 
Regarding sex differences, similar to previous studies [23], female participants were 
significantly faster metabolizers than men. Our findings suggest that women might 
experience more negative effects during abstinence. The higher NMR and withdrawal do not 
offer an explanation regarding the fewer CPD reported in women, which may be associated 
with non-nicotine related behavior factors.  
Concordance between genotype and NMR was not complete. Although several CYP2A6 gene 
variants have been shown to have an effect on smoking behavior [21,34], the currently 
identified variants explain only a small percentage of the variation in nicotine metabolism 
[7,35]. In a recent genome wide association study of NMR, over 700 significantly associated 
variants were identified on chromosome 19q13 (the loci of CYP2A6) [36]; further 
characterization will improve utility of the CYP2A6 genotype. In addition, there are likely 
unaccounted for effects of UGT and other genetic variations and hormonal and environmental 
effects. Next to estrogen, other substances (e.g. phenobarbital, rifampin, broccoli) can induce 
CYP2A6, while others (e.g. grapefruit, menthol) can inhibit its activity [21]. It is therefore 
not surprising that the CYP2A6 genotype did not predict outcomes as well as the NMR.   
Limitations of our study include that, despite our intention, achieved plasma nicotine baseline 
after the loading cigarettes was not equal in the two NMR groups. The number of Blacks and 
women were relatively small. Furthermore, we studied only six hours abstinence, while 
longer abstinence periods would be associated with more intense withdrawal/craving, and 
factors other than nicotine dependence might also affect the desire to smoke/craving for 
tobacco. Despite these limitations, the present study clearly demonstrates in a prospectively 
stratified design that high NMR is associated with lower blood nicotine levels and higher 
craving/withdrawal during brief smoking abstinence. 
In conclusion, our study provides evidence that fast metabolizers by NMR are likely smoking 
more for negative reinforcement, i.e. to relieve craving/withdrawal symptoms and to a lesser 
extent if at all due to positive reinforcement, i.e. greater reward effects after smoking. The 
non-invasive saliva NMR appears to be a better biomarker of withdrawal/craving effects than 
the CYP2A6 genotype. 
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Methods   
Participants and recruitment: Participants were healthy or with stable medical or psychiatric 
conditions volunteers, between the ages of 18 and 70, of self-reported African American or 
Caucasian descent (both parents and grandparents of same race), who smoked at least five 
CPD regularly for the last year. Participants were recruited through Craigslist, flyers, and 
newspaper ads. At an initial screening visit, medical history was provided by a questionnaire. 
A physical exam was performed upon entry on the research ward. Participants provided a 
saliva sample for COT to verify smoking status (i.e. COT ≥ 50 ng/mL) and to assess NMR, 
and they completed a demographics, the Fagerstrom Test for Cigarette Dependence (FTCD) 
(including TFC and CPD) [37], and questions regarding amount and frequency of alcohol 
use. Based on the saliva NMR, participants were stratified as fast or slow metabolizers. Based 
on prior studies [38], cut points were ≤ 0.20 and ≥ 0.37 in Blacks, and ≤ 0.26 and ≥ 0.45 in 
Whites (all within 0.01). The study was approved by the University of California San 
Francisco Institutional Review Board. 
Study procedures: Eligible participants were admitted to the research ward at Zuckerberg San 
Francisco General Hospital the evening before the study to enforce 12 hours overnight 
abstinence (last cigarette at 9 PM). In the evening, a urine sample was collected for TNE. In 
the morning of the study day, participants had an intravenous catheter inserted for blood 
drawing and a light breakfast was served. One hour later (~9 AM) participants smoked two 
cigarettes (Marlboro Regular for non-menthol smokers and Marlboro Menthol for menthol 
smokers) with a standardized puffing protocol (i.e. one puff of two seconds duration every 38 
seconds for a total of ten puffs from each cigarette). The second cigarette (Cig 2) was smoked 
approximately 26 minutes after Cig 1. These “loading cigarettes” were intended to relieve 
overnight withdrawal symptoms and place participants in a similar nicotine-satiated baseline 
state across the study groups. Participants then abstained from smoking for six hours, which 
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represents on average three half-lives of nicotine, allowing an estimate of elimination half-
life, and also adequate time for the development of significant withdrawal/craving symptoms 
[39-41]. After six hours daytime abstinence, a third cigarette (Cig 3) of the smoker’s own 
brand was smoked in their usual way. This “reward cigarette” was followed by a 90-minute 
period of monitored “free” ad libitum smoking (these results will be described in another 
publication). A modified version of the MNWS [42] was administered before Cig 1 and Cig 
3, immediately after Cig 1, Cig 2, and Cig 3 and 2 and 4 hours after Cig 2. The QSU [43] was 
administered at the same time points with the MNWS, as well as 1, 3 and 5 hours after Cig 2. 
The mCES [44] was administered after each cigarette. The PANAS [45] was assessed before 
Cig 1 and Cig 3, as well as immediately, 2 and 4 hours after Cig 2 and immediately after Cig 
3. Nicotine blood concentrations were measured before and 2 minutes after each loading 
cigarette, then 30 minutes, 1, 2, 3, 4 and 5 hours after Cig 2, and before and 2 minutes after 
Cig 3. One sample (baseline) was also used to calculate plasma NMR in order to validate 
saliva NMR. CO and HR were measured before each blood sample. 
Study measures: The modified MNWS (excluding items relating to sleep disturbance and 
constipation) included eight items (angry/irritable/frustrated, anxious/nervous, depressed 
mood/sad, desire or craving to smoke, difficulty concentrating, increased appetite/hungry, 
restless and impatient), rated on a 0=none to 4=severe scale. The QSU total (global) craving 
score is the average of all responses (mean of ten items, rated on a 1=strongly disagree to 
7=strongly agree scale). The mCES (total of 12 items) was used to assess satisfaction (three 
items), psychological reward (five items), aversion (two items), craving reduction (one item) 
and respiratory tract sensations as responses to smoking (one item). The mCES is rated on a 
1=not at all to 7=extremely scale, and scoring is done by adding the item scores for each 
scale. The PANAS included items assigned as Positive or Negative Affect (each score is the 
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sum of ten items, rated on a 1=very slightly/not at all to 5=extremely scale). Plasma nicotine 
and CO boosts represent changes in levels between pre- and post-smoking. 
Laboratory methods: Saliva 3HC and COT were measured by liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) [46], plasma nicotine by gas chromatography-tandem mass 
spectrometry [47] (LOQ 1 ng/mL). TNE in urine was calculated by taking total (molar sum of 
free and glucuronide conjugate) of six metabolites of nicotine (nicotine, COT, 3-
hydroxycotinine, nicotine-n-oxide, cotinine-n-oxide, nornicotine and norcotinine) assayed by 
LC-MS/MS and normalized by urine creatinine [2].  
Genotyping of CYP2A6*1X2, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*20, 
CYP2A6*23, CYP2A6*24, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28 and 
CYP2A6*35 was performed at the University of Toronto according to previously described 
protocols [18,48]. Those without variants (or with the duplication CYP2A6*1x2 variant) were 
characterized as NM, those with a single copy of CYP2A6*9 or CYP2A6*12 as intermediate 
metabolizers and those with two copies, or any other reduced or loss of function variant as 
slow metabolizers. For analyses using the genotype, slow and intermediate metabolizers were 
grouped together as RM.  
Data cleaning and analysis: Numerical data are presented as arithmetic mean and standard 
deviation if normally distributed or median and range if not normally distributed, nominal 
data as proportion (%). Measurements below LOQ were replaced by LOQ/   [49]. Since 
creatinine levels can vary by sex, age, BMI, and race, we also used a covariate-adjusted 
standardization method [50] to control measurement error bias. Skewed score values were log 
transformed before analysis. Differences were tested using the chi-square test for categorical 
variables, the t test for normally distributed continuous variables, and the Mann Whitney test 
for nonparametric variables. Missing data were not imputed. A p<0.05 was considered 
statistically significant. Subjective withdrawal (MNWS) and craving (QSU) effects were also 
determined as the AUEC using the trapezoidal method. Next to our main analysis 
investigating differences between slow and fast NMR, we also performed an additional 
analysis of Whites and Blacks only to investigate possible racial differences. Furthermore, in 
an additional explorative analysis we included sex and race that have been shown to influence 
NMR as covariates in a GLM, with fast and slow NMR entered as a categorical between-
subject factor predicting withdrawal and reward outcomes. Other covariates (i.e. age, BMI, 
creatinine-corrected TNE, covariate-adjusted TNE) were also individually explored for their 
potential contributions on the NMR effects. For withdrawal after overnight abstinence and 
reward outcomes after each cigarette a univariate GLM was used, while for the six hour 
abstinence period a repeated measures GLM over time was used with the first time point (i.e. 
post-Cig 2) as covariate. Analyses were conducted using SPSS statistical software (IBM 
SPSS Statistics 23.0). Covariate adjustment of TNE was performed using SAS v. 9.4 (SAS 
Institute, Inc., Cary, NC, USA). Nicotine elimination half-lives were estimated from plasma 
nicotine concentrations using Phoenix WinNonlin 6.3 (Pharsight Corporation, Mountain 
View, CA). 
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Study highlights:  
 What is the current knowledge on the topic?  
The nicotine metabolite ratio (NMR) is a phenotypic biomarker that is highly 
correlated with the rate of nicotine clearance, which is an important determinant of 
smoking behavior and nicotine dependence. 
 What question did this study address? 
The present study aimed to examine the effect of NMR on nicotine withdrawal 
symptoms and the response to smoking a cigarette after overnight abstinence and six 
hours daytime abstinence. 
 What does this study add to our knowledge? 
Fast metabolizers by NMR had lower blood nicotine concentrations and greater 
craving/withdrawal scores compared to slow metabolizers, but not greater reward 
after smoking, thus supporting the idea that fast metabolizers are likely smoking more 
to relieve craving/withdrawal symptoms. 
 How might this change clinical pharmacology or translational science? 
Selection of medications and/or doses of medications based on the importance of 
relieving craving and nicotine withdrawal symptoms, guided by NMR, may be useful 
in optimizing smoking cessation therapy.  
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Figure Legends 
 
Figure 1. Frequency of slow and fast NMR in the CYP2A6 genotype groups (n=124) 
 
Figure 2. Average plasma nicotine concentrations over time based on a. NMR and b. 
Genotype (*=p<0.05, #=p<0.001 for differences between groups)  
 
Figure 3. Average Minnesota Nicotine Withdrawal Scale (MNWS) score over time based on 
a. NMR and b. Genotype (*=p<0.05 for differences between groups) 
 
Figure 4. Average Questionnaire on Smoking Urges (QSU) Global Craving Score over time 
based on a. NMR and b. Genotype (*=p<0.05 for differences between groups) 
Supplementary Material 
 
Figure S1. NMR frequency histogram 
 
Table S1. Comparisons of slow and fast metabolizers in the two racial subgroups (mean (standard 
deviation), median (range) or n (%)) 
 
Table S2. Comparisons of slow and fast metabolizers in the two sex subgroups (mean (standard 
deviation), median (range) or n (%)) 
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Table 1. Baseline characteristics (mean (standard deviation), median (range) or n (%)) 
 All 
(n=136) 
Slow NMR 
(n= 71) 
Fast NMR 
(n=65) 
p Whites 
(n=98) 
Blacks 
(n=38) 
p Male 
(n=83) 
Female 
(n=53) 
p 
Age  
(years) 
36.3 
(12.3) 
34.4 
(12.3) 
38.3 
(12) 
0.065 35 
(12.1) 
39.6 
(12.3) 
0.05 34.7 
(11.5) 
38.8 
(13.1) 
0.054 
Sex  
(female) 
53 
(39%) 
21 
(30%) 
32 
(49%) 
0.019 35 
(36%) 
18 
(47%) 
0.211 na na na 
Race  
(Blacks) 
38 
(28%) 
22 
(31%) 
16 
(25%) 
0.408 na na na 20 
(24%) 
18 
(34%) 
0.211 
BMI 25.7 
(4.6) 
25.6 
(4.6) 
25.8 
(4.7) 
0.793 25.1 
(4.6) 
27.2 
(4.1) 
0.016 25.5  
(4.3) 
25.9 
(5.1) 
0.649 
FTCD 4.2  
(2.1) 
4.3 
(2.1) 
4.1 
(2.2) 
0.69 4.3 
(2.1) 
3.8 
(2.2) 
0.15 4 
(2.1) 
4.3 
(2.2) 
0.495 
CPD 12 
(5-40) 
12 
(5-40) 
13 
(5-35) 
0.42 13 
(5-40) 
10 
(5-20) 
0.001 13 
(5-40) 
10 
(5-30) 
0.054 
Years of smoking  14.5 
(2-43) 
13 
(2-43) 
15 
(2-41) 
0.231 13.5 
(2-43) 
16 
(2-43) 
0.515 15 
(2-43) 
14 
(2-41) 
0.561 
TFC 
(minutes) 
30 
(0.5-480) 
20 
(0.5-180) 
30 
(2-480) 
0.033 28 
(1-480) 
30 
(0.5-240) 
0.967 30 
(0.5-480) 
30 
(2-240) 
0.682 
Alcohol grams per 
week  
(self-reported) 
37 
(0-486) 
41 
(0-486) 
13 
(0-235) 
0.156 42.5 
(0-486) 
13 
(0-333) 
0.13 52 
(0-390) 
10 
(0-486) 
<0.001 
Menthol cigarettes  38  20 18 0.95 14 24 <0.001 21 17 0.39 
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(28%) (28%) (28%) (14%) (63%) (25%) (32%) 
Saliva COT  
(ng/mL) 
145.2 
(48.2-653.8) 
189.8 
(48.2-653.8) 
119.3 
(49.5-481.7) 
<0.001 138.3 
(48.2-653.8) 
148.2 
(74-610.3) 
0.308 147.8 
(48.2-653.8) 
137.5 
(52.4-481.7) 
0.384 
Saliva NMR  0.25 
(0.06-1.32) 
0.16 
(0.06-0.27) 
0.55 
(0.37-1.32) 
<0.001 0.36 
(0.07-1.32) 
0.19 
(0.06-0.57) 
0.005 0.21 
(0.08-1.32) 
0.46 
(0.06-1.1) 
0.034 
Plasma NMR  
 
0.39  
(0-2) 
0.27  
(0-1) 
0.66 
(0-2) 
<0.001 0.45 
(0-2) 
0.33 
(0-2) 
0.007 0.36  
(0-2) 
0.46 
(0-2) 
0.044 
Nicotine elimination  
half-life  
(minutes) 
111.3 
(41.1-272.4) 
130.4 
(50.3-255.5) 
93.0 
(41.1-272.4) 
<0.001 105.9 
(41.1-272.4) 
151.2 
(50.3-255.5) 
0.001 112.0 
(50-272.4) 
109.1 
(41.1-255.5) 
0.854 
Urine TNE  
(nmol/mg creat)  
53.3 
(0.9-195.5) 
51.6 
(1-195.5) 
55.0 
(0.9-173.8) 
0.812 62.1 
(1-195.5) 
36.8 
(0.9-116.2) 
0.009 45.0 
(3.9-195.5) 
67.4 
(0.9-150.2) 
0.098 
NMR: nicotine metabolite ratio; BMI: body mass index; FTCD Fagerstrom Test for Cigarette Dependence; CPD: cigarettes per day; TFC: time to first cigarette after 
awakening in the morning; COT: cotinine; TNE: total nicotine equivalents 
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Table 2. Associations of NMR with withdrawal and physiological measurements (mean 
(standard deviation) or median (range)) 
 
 After overnight abstinence (i.e. before Cig 1) After six hours abstinence (i.e. before Cig 3) 
 All  
(n=136) 
Slow NMR 
(n= 71) 
Fast NMR 
(n=65) 
p All  
(n=136) 
Slow NMR 
(n= 71) 
Fast NMR 
(n=65) 
p 
Plasma nicotine 
(ng/mL) 
1.0  
(0.7-6.7) 
1.5  
(0.7-6.7) 
0.7  
(0.7-6.6) 
<0.001 1.4  
(0.7-8.9) 
2.25 
 (0.7-8.9) 
1.2  
(0.7-3.4) 
<0.001 
Expired CO 
(ppm) 
9 
(2-22) 
9  
(3-22) 
8  
(2-21) 
0.31 8 
(2-16) 
9  
(3-16) 
8  
(2-14) 
0.022 
HR 69.8  
(9.1) 
69.6  
(9.4) 
70  
(8.9) 
0.816 72.2  
(10.2) 
72.4  
(10.2) 
72  
(10.2) 
0.804 
QSU global 
craving score  
4  
(1-7) 
3.9  
(1-6.4) 
4.3  
(1-7) 
0.203 3.85  
(1-7) 
3.7 
 (1-7) 
3.9  
(1.5-7) 
0.016 
MNWS 7  
(0-32) 
6  
(0-22) 
8  
(1-32) 
0.087 8  
(0-48) 
8  
(0-21) 
9  
(1-48) 
0.057 
PANAS negative 12  
(10-35) 
12  
(10-24) 
13  
(10-35) 
0.178 11  
(10-30) 
11  
(10-20) 
12  
(10-30) 
0.059 
PANAS positive 26 
(3-46) 
26.5 
(3-45) 
26 
(11-46) 
0.790 24 
(10-50) 
24 
(10-50) 
22 
(10-50) 
0.493 
NMR: nicotine metabolite ratio; CO: carbon monoxide; HR: heart rate; QSU: Questionnaire on Smoking Urges; 
MNWS: Minnesota Nicotine Withdrawal Scale; PANAS: Positive and Negative Affect Scale 
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Table 3. Associations of NMR with the response to smoking after abstinence (mean (standard deviation) or median (range))  
 
 After first cigarette of the day  
(i.e. after Cig 1, except indicated otherwise) 
After Cig 3  
 All  
(n=136) 
Slow NMR  
(n= 71) 
Fast NMR 
(n=65) 
p All  
(n=136) 
Slow NMR  
(n= 71) 
Fast NMR 
(n=65) 
p 
Plasma nicotine (ng/mL) 12.9  
(0.7-40.8) 
13.6  
(2.2-40.8) 
10.9  
(0.7-32.3) 
0.038 17.3  
(3.6-51.8) 
18.2  
(6.1-51) 
16.2  
(3.6-51.8) 
0.077 
Expired CO  
(ppm) 
15  
(6-32) 
16  
(8-32) 
15  
(6-29) 
0.107 16 
 (3-42) 
16 
 (7-42) 
16  
(3-31) 
0.097 
HR 85.5  
(12.7) 
84  
(12.4) 
87.1  
(12.9) 
0.149 85.1  
(11.2) 
83.9  
(11.4) 
86.3  
(10.9) 
0.224 
QSU global craving score 1.3  
(1-7) 
1.2  
(1-4.8) 
1.6  
(1-7) 
0.022 1.2  
(1-5.5) 
1.1  
(1-4.9) 
1.4  
(1-5.5) 
0.067 
MNWS 4  
(0-22) 
3  
(0-22) 
5  
(0-21) 
0.02 3  
(0-17) 
3  
(0-15) 
4  
(0-17) 
0.512 
PANAS negative  11  
(10-35)
£
 
11  
(10-35)
£
 
12  
(10-28)
£
 
0.508 11 
(10-28) 
11 
(10-26) 
11  
(10-28) 
0.393 
PANAS positive 26  
(10-47)
£
 
25  
(10-47)
£
 
26  
(10-43)
£
 
0.613 25  
(10-50) 
26 
(10-50) 
24  
(10-48) 
0.732 
mCES aversion 6  6  6  0.128 4  4  4  0.552 
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(2-14) (2-14) (2-13) (2-13) (2-12) (2-13) 
mCES craving 6  
(1-7) 
6  
(1-7) 
6  
(1-7) 
0.207 6  
(1-7) 
6  
(1-7) 
6  
(1-7) 
0.235 
mCES reward 18  
(5-35) 
18  
(5-35) 
17  
(5-35) 
0.624 17  
(5-35) 
16  
(5-35) 
18  
(5-35) 
0.247 
mCES satisfaction 14.5  
(3-21) 
16  
(3-21) 
12  
(3-21) 
0.048 15  
(3-21) 
15  
(3-21) 
15  
(4-21) 
0.482 
 mCES respiratory tract sensations 4  
(1-7) 
4  
(1-7) 
3  
(1-7) 
0.421 4  
(1-7) 
4  
(1-7) 
4  
(1-7) 
0.205 
NMR: nicotine metabolite ratio; CO: carbon monoxide; HR: heart rate; QSU: Questionnaire on Smoking Urges; MNWS: Minnesota Nicotine Withdrawal Scale; PANAS: 
Positive and Negative Affect Scale; mCES: modified Cigarette Evaluation Scale 
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